Eleftha 150mg Injection

About this Medicine

Eleftha 150mg Injection is used in the treatment of breast and stomach cancer. It works by killing the cancer cells by inhibiting HER2 (human epidermal growth factor receptor protein). Eleftha 150mg Injection is given as an injection by a qualified medical professional. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.The most common side effects of this medicine include nausea, headache, rash, insomnia, and infection. This medicine may reduce the number of blood cells (decrease red blood and white blood cells) in your blood, thereby, increasing the susceptibility to infections. Regular blood tests are required to check your blood cells along with heart, liver, and blood uric acid levels. You must have to inform your doctor if you experience breathlessness, cough, shivering, swelling of legs and arm.Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy.

How it Works

Eleftha 150mg Injection is a recombinant IgG1 monoclonal antibody. It works against the HER2 (human epidermal growth factor receptor protein) receptors which are responsible for the over-proliferation of cancer cells in breast cancer and stomach cancer cells. It destroys the cancer cells by inhibiting HER2. It also inhibits various cancer-causing downstream signaling pathways.

Key Facts

Chemical Class :: Monoclonal antibody (mAb)|Habit Forming :: No|Therapeutic Class :: ANTI NEOPLASTICS|Action Class :: HER2/neu (ErbB2) Inhibitor- Monoclonal antibody

Safety Overview